MX382809B - Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores. - Google Patents
Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores.Info
- Publication number
- MX382809B MX382809B MX2016016122A MX2016016122A MX382809B MX 382809 B MX382809 B MX 382809B MX 2016016122 A MX2016016122 A MX 2016016122A MX 2016016122 A MX2016016122 A MX 2016016122A MX 382809 B MX382809 B MX 382809B
- Authority
- MX
- Mexico
- Prior art keywords
- tm9sf4
- extracellular vesicles
- biomarker
- tumor
- isolating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G01N33/575—
-
- G01N33/57585—
-
- G01N33/5759—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un método para determinar in vitro la presencia de un tumor en un sujeto, el método comprende: a) proporcionar una muestra biológica obtenida a partir de ese sujeto, b) aislar vesículas extracelulares a partir de la muestra, en donde esta etapa de aislamiento de vesículas extracelulares comprende el aislamiento de vesículas extracelulares positivas a TM9SF4, c) determinar, a partir de las vesículas extracelulares aisladas en la etapa b), el nivel o presencia de un biomarcador adecuado, y d) comparar el nivel o presencia del biomarcador determinado en la etapa c) con uno de referencia, caracterizado porque las vesículas extracelulares positivas a TM9SF4 se aíslan a través de la unión a un anticuerpo anti-TM9SF4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14171464 | 2014-06-06 | ||
| PCT/EP2015/062594 WO2015185730A2 (en) | 2014-06-06 | 2015-06-05 | Exosomal biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016122A MX2016016122A (es) | 2017-04-27 |
| MX382809B true MX382809B (es) | 2025-03-13 |
Family
ID=50896184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016122A MX382809B (es) | 2014-06-06 | 2015-06-05 | Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170146543A1 (es) |
| EP (1) | EP3152576B1 (es) |
| JP (1) | JP6650929B2 (es) |
| CN (2) | CN113092764A (es) |
| AU (1) | AU2015270450B2 (es) |
| CA (1) | CA2950977C (es) |
| ES (1) | ES2700404T3 (es) |
| MX (1) | MX382809B (es) |
| PL (1) | PL3152576T3 (es) |
| RU (1) | RU2712223C2 (es) |
| WO (1) | WO2015185730A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018070479A1 (ja) * | 2016-10-13 | 2018-04-19 | 合同会社みらか中央研究所 | 細胞外小胞の回収方法 |
| US12404554B2 (en) * | 2017-06-21 | 2025-09-02 | Exosomics S.p.A. | Methods and kits relating to the capture of CA-IX positive exosomes |
| US11284222B2 (en) | 2017-12-14 | 2022-03-22 | Sony Corporation | Communication apparatus, communication method, and program for communicating with directional beams |
| EP3775882A1 (en) * | 2018-03-30 | 2021-02-17 | Exosomics S.P.A. | Use of hollow fibers to obtain blood or a blood derivative impoverished from blood cells and platelets derived extracellular vesicles |
| RU2705344C1 (ru) * | 2019-03-15 | 2019-11-06 | Ольга Алексеевна Фишер | Способ скрининга рака молочной железы и предрасположенности к нему |
| WO2021146659A1 (en) * | 2020-01-17 | 2021-07-22 | Mercy Bioanalytics, Inc. | Compositions and methods for detection of ovarian cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120122118A1 (en) * | 2008-01-25 | 2012-05-17 | Primm Srl | Monclonal antibodies, hybridomas and methods for use |
| US20120058492A1 (en) * | 2008-01-25 | 2012-03-08 | Hansabiomed Ou | Method and a Kit To Detect Malignant Tumors and Provide a Prognosis |
| US8617806B2 (en) * | 2008-01-25 | 2013-12-31 | Hansabiomed Ou | Method to measure and characterize microvesicles in the human body fluids |
| JP5752419B2 (ja) * | 2008-01-25 | 2015-07-22 | ハンサビオメド・オサウヒング | 新規ヒト転移性腫瘍関連分子、活性化遺伝子およびタンパク質を検出する方法ならびに遺伝子発現を妨害する方法 |
| EP2730662A1 (en) * | 2008-11-12 | 2014-05-14 | Caris Life Sciences Luxembourg Holdings | Methods and systems of using exosomes for determining phenotypes |
| WO2012048372A1 (en) * | 2010-10-11 | 2012-04-19 | Medsaic Pty Ltd | Assay for disease detection |
| CN103197066B (zh) * | 2013-03-07 | 2015-12-23 | 美国纳米材料创新有限公司 | 一种免疫脂质体生物芯片、其制备方法及其在生物检测中的应用 |
-
2015
- 2015-06-05 CA CA2950977A patent/CA2950977C/en active Active
- 2015-06-05 EP EP15726199.1A patent/EP3152576B1/en active Active
- 2015-06-05 CN CN202110389013.2A patent/CN113092764A/zh active Pending
- 2015-06-05 AU AU2015270450A patent/AU2015270450B2/en active Active
- 2015-06-05 JP JP2017516203A patent/JP6650929B2/ja active Active
- 2015-06-05 WO PCT/EP2015/062594 patent/WO2015185730A2/en not_active Ceased
- 2015-06-05 PL PL15726199T patent/PL3152576T3/pl unknown
- 2015-06-05 CN CN201580042674.0A patent/CN106574928A/zh active Pending
- 2015-06-05 RU RU2016152346A patent/RU2712223C2/ru active
- 2015-06-05 US US15/316,188 patent/US20170146543A1/en not_active Abandoned
- 2015-06-05 MX MX2016016122A patent/MX382809B/es unknown
- 2015-06-05 ES ES15726199T patent/ES2700404T3/es active Active
-
2022
- 2022-05-05 US US17/737,453 patent/US20220349892A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016016122A (es) | 2017-04-27 |
| US20220349892A1 (en) | 2022-11-03 |
| JP2017518517A (ja) | 2017-07-06 |
| AU2015270450B2 (en) | 2021-04-01 |
| PL3152576T3 (pl) | 2019-01-31 |
| CN106574928A (zh) | 2017-04-19 |
| AU2015270450A1 (en) | 2017-01-05 |
| JP6650929B2 (ja) | 2020-02-19 |
| CA2950977A1 (en) | 2015-12-10 |
| ES2700404T3 (es) | 2019-02-15 |
| WO2015185730A2 (en) | 2015-12-10 |
| CN113092764A (zh) | 2021-07-09 |
| EP3152576A2 (en) | 2017-04-12 |
| RU2016152346A3 (es) | 2019-03-18 |
| WO2015185730A3 (en) | 2016-02-18 |
| RU2016152346A (ru) | 2018-07-09 |
| RU2712223C2 (ru) | 2020-01-27 |
| US20170146543A1 (en) | 2017-05-25 |
| EP3152576B1 (en) | 2018-09-12 |
| CA2950977C (en) | 2023-10-10 |
| BR112016028581A2 (en) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20170230A (es) | Anticuerpos anti-cd79b y métodos de uso | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX2017015464A (es) | Anticuerpos anti-tau y metodos de uso. | |
| CO2017004516A2 (es) | Anticuerpos anti-ox40 humanizados | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
| MX2024011869A (es) | Anticuerpos anti-tau y metodos de uso | |
| IL281355B (en) | Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm | |
| GEAP202114453A (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| LT3183268T (lt) | Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui | |
| MX2017000419A (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| MX2017000116A (es) | Moleculas basadas en il-15 y metodos para su uso. | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| CR20140382A (es) | Anticuerpos anti-lrp5 y metodos de uso | |
| MX382809B (es) | Uso de tm9sf4 como un biomarcador para exosomas asociadas con tumores. | |
| WO2015187018A3 (en) | Means and methods for determining t cell recognition | |
| EP3597766A4 (en) | NEW BIOMARKER FOR ANTI-CANCER IMMUNOTHERAPY | |
| EP3546947A3 (en) | Biomarker panels for brain injury complications | |
| EP3679069C0 (en) | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER | |
| MX384037B (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. |